|
1) Thomas MB, O'Beirne JP, Furuse J, et al. Systemic therapy for hepatocellular carcinoma: Cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol. 2008; 15: 1008-14
|
|
|
|
2) Butterfield LH. Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology. 2004; 127: S232-41
|
|
|
|
|
|
3) Palmer DH, Hussain SA, Johnson PJ. Gene- and immunotherapy for hepatocellular carcinoma. Expert Opin Biol Ther. 2005; 5: 507-23
|
|
|
|
|
|
4) Avila MA, Berasain C, Sangro B, et al. New therapies for hepatocellular carcinoma. Oncogene. 2006; 25: 3866-84
|
|
|
|
|
|
5) Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med. 2001: 134: 963-7
|
|
|
|
|
|
6) Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology. 2000; 31: 54-8
|
|
|
|
|
|
7) Sakon M, Nagano H, Dono K, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer. 2002; 94: 435-42
|
|
|
|
|
|
8) Ota H, Nagano H, Sakon M, et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type I interferon receptor expression. Br J Cancer. 2005; 93: 557-64
|
|
|
|
|
|
9) Obi S, Yoshida H, Toune R, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2006; 106: 1990-7
|
|
|
|
|
|
10) Mawatari H, Kirikoshi H, Yoneda M, et al. Effective treatment of advanced hepatocellular carcinoma with portal venous invasion using a combination therapy of intra-arterial 5-fuluorourasil and subcutaneous pegylated-interferon-α2b. Hepatogastroenterology. 2008; 55: 1776-7
|
|
|
|
|
|
11) Ueshima K, Kudo M, Nagai T, et al. Combination therapy with S-1 and pegylated interferonα for advanced hepatocellular carcinoma. Oncology. 2008; 75(suppl1): 106-13
|
|
|
|
|
|
12) Nakamura M, Nagano H, Marubashi S, et al. Pilot study of combination of S-1, a novel oral DPD inhibitor, and interferon-α for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer. 2008; 112: 1765-71
|
|
|
|
|
|
13) Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patinets with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987; 316: 889-97
|
|
|
|
|
|
14) Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000; 356: 802-7
|
|
|
|
|
|
15) Takeda T, Watanabe M, Umeshita K, et al. Long-term prognosis of hepatocellular carcinoma patients treated with adoptive immunotherapy. Jpn J Cancer Chemother. 2004; 31: 1646-8
|
|
|
|
|
|
16) Shi M, Zhang B, Tang ZR, et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterology. 2004; 10: 1146-51
|
|
|
|
|
|
17) Gonzalez-Carmona MA, Lukacs-Kornek V, Timmerman A, et al. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo. Hepatology. 2008; 48: 157-68
|
|
|
|
|
|
18) Ladhams A, Schmidt C, Sing G, et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol. 2002; 17: 889-96
|
|
|
|
|
|
19) Iwashita Y, Tahara K, Goto S, et al. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother. 2003; 52: 155-61
|
|
|
|
|
|
20) Lee WC, Wang HC, Hung CF, et al. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother. 2005; 28: 496-505
|
|
|
|
|
|
21) Nakamoto Y, Mizukoshi E, Tsuji H, et al. Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety. Clin Exp Immunol. 2007; 147: 296-305
|
|
|
|
|
|
22) Palmer DH, Midgley RS, Mizra N, et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology. 2009; 49: 124-32
|
|
|
|
|
|
23) Mizukoshi E, Nakamoto Y, Tsuji H, et al. Identification of α-fetoprotein-derived peptides recognized by cytooxic T lymphocytes in HLA-A24＋ patients with hepatocellular carcinoma. Int J Cancer. 2006; 118: 1194-204
|
|
|
|
|
|
24) Butterfield LH, Ribas A, Meng WS, et al. T-cell responses to HLA-A＊0201 immunodominant peptides derived from a-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res. 2003; 9: 5902-8
|
|
|
|
|
|
25) Bricard G, Bouzourene H, Martinet O, et al. Naturally acquired MAGE-A10- and SSX-2-specific CD8＋ T cell responses in patients with hepatocellular carcinoma. J Immunol. 2005; 174: 1709-16
|
|
|
|
|
|
26) Shang XY, Chen HS, Zhang HG, et al. The spontaneous CD8＋ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin Cancer Res. 2004; 10: 6946-55
|
|
|
|
|
|
27) Zhang HG, Chen HS, Peng JR, et al. Specific CD8(＋) T cell responses to HLA-A2 restricted MAGE-A3 p271-279 peptide in hepatocellular carcinoma patients without vaccination. Cancer Immunol Immunother. 2007; 56: 1945-54
|
|
|
|
|
|
28) Komori H, Nakatsura T, Senju S, et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res. 2006; 12: 2689-97
|
|
|
|
|
|
29) Motomura Y, Ikuta Y, Kuronuma T, et al. HLA-A2 and A24-restricted glypican-3 derived peptide vaccine specific CTLs: preclinical study using mice. Int J Oncol. 2008; 32: 985-90
|
|
|
|
|
|
30) Butterfield LH, Ribas A, Dissette VB, et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res. 2006; 12: 2817-25
|
|
|
|
|
|
31) Tanaka S, Arii S. Molecular targeted therapy for hepatocellular carcinoma. Cancer Sci. 2009; 100: 1-8
|
|
|
|
|
32) Armeanu S, Krusch M, Baltz KM, et al. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res. 2008; 14: 3520-8
|
|
|
|
|
|
33) Kohga K, Takehara T, Tatsumi T, et al. Serum levels of major histocompatibility complex (MHC) class I-related chain A in patients with chronic diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma. Cancer Sci. 2008; 99: 1643-9
|
|
|
|
|
|
34) Doherty DG, O'Farrelly C. Innate and adaptive lymphoid cells in human liver. Immunol Rev. 2000; 174: 5-20
|
|
|
|
|
|
35) Tatsumi T, Takehara T, Yamaguchi S, et al. Intrahepatic delivery of α-galactosylceramide-pulsed dendritic cells suppresses liver tumor. Hepatology. 2007; 45: 22-30
|
|
|
|
|
|
36) Suetsugu A, Nagaki M, Aoki H, et al. Characterization of CD133＋ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun. 2006; 351: 820-4
|
|
|
|
|
|
37) Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007; 132: 2542-56
|
|
|
|
|
|
38) Yin S, Li J, Hu C, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007; 120: 1436-42
|
|
|
|
|
|
39) Yang ZF, Ho DW, Ng MN, et al. Significance of CD90＋ cancer stem cells in human liver cancer. Cancer Cell. 2008; 13: 153-66
|
|
|
|
|
|
40) Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009; 136: 1012-24
|
|
|
|
|
|
41) Yamashita T, Forgues M, Wang W, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008; 68: 1451-61
|
|
|
|
|